{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-179958","form_type":"8-K","ticker":"CMPX","cik":"0001738021","company_name":"Compass Therapeutics, Inc.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.845249+00:00","generated_at":"2026-05-17T13:57:46.142617+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Compass Therapeutics prices $120M upsized public offering of common stock and pre-funded warrants","bullets":["Priced upsized $120M offering: 33.29M shares at $3.00/share and 6.71M pre-funded warrants at $2.9999 each.","Net proceeds estimated at $112.5M (base), up to $129.5M if underwriters' 30-day option for 6M additional shares is exercised.","Proceeds to fund commercial readiness, R&D of product candidates, and general corporate purposes.","Cash and equivalents expected to fund operations into 2028.","Jefferies, Piper Sandler, and Guggenheim Securities are joint bookrunners."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-179958","json":"https://secwatch.observer/filing/0001193125-25-179958.json","markdown":"https://secwatch.observer/filing/0001193125-25-179958.md","text":"https://secwatch.observer/filing/0001193125-25-179958.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1738021/000119312525179958/0001193125-25-179958-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1738021/000119312525179958/d153873d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:57:46.142617+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}